Fluoxetine versus sertraline in the treatment of patients with undifferentiated somatoform disorder: A randomized, open-label, 12-week, parallel-group trial

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 2, 2008, Pages 437-444

  Han, Changsu ^a,b   Pae, Chi Un ^a,c   Lee, Bun Hee ^a   Ko, Young Hoon ^a   Masand, Prakash S ^b   Patkar, Ashwin A ^b   Jung, In Kwa ^a  

^a Korea University College of Medicine   (South Korea)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c The Catholic University of Korea   (South Korea)

Author keywords

Fluoxetine; Open label; Patient Health Questionnaire; Sertraline; Undifferentiated somatoform disorder

Indexed keywords

FLUOXETINE; SERTRALINE;

ANOREXIA; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG TOLERABILITY; GENERAL HEALTH QUESTIONNAIRE; HUMAN; INSOMNIA; NAUSEA; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMATOFORM DISORDER; SOMNOLENCE; SWEATING; TREATMENT DURATION; VOMITING; XEROSTOMIA;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOXETINE; HEALTH STATUS; HUMANS; MALE; PERSONALITY INVENTORY; QUESTIONNAIRES; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SEVERITY OF ILLNESS INDEX; SOMATOFORM DISORDERS; TREATMENT OUTCOME;

EID: 38749088722     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.09.014     Document Type: Article

References (53)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed (1994), American Psychiatric Association Press, Washington, DC
2. Allgulander C., Dahl A.A., Austin C., Morris P.L., Sogaard J.A., Fayyad R., et al. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry 161 (2004) 1642-1649
3. Aragona M., Bancheri L., Perinelli D., Tarsitani L., Pizzimenti A., Conte A., et al. Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) reuptake inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder. Eur J Pain 9 (2005) 33-38
4. Arnold L.M., Hess E.V., Hudson J.I., Welge J.A., Berno S.E., and Keck Jr. P.E. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 112 (2002) 191-197
5. Arnold I.A., de Waal M.W., Eekhof J.A., and van Hemert A.M. Somatoform disorder in primary care: course and the need for cognitive-behavioral treatment. Psychosomatics 47 (2006) 498-503
6. Beck A.T., Ward C.H., Mendelson M., Mock J., and Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 4 (1961) 561-571
7. Belous A.R., Ramamoorthy S., Blakely R.D., Factor M.I., Dupin A.M., Katasonov A.B., et al. The state of the serotonin transporter protein in the platelets of patients with somatoform [correction of somatiform] disorders. Neurosci Behav Physiol 31 (2001) 185-189
8. Chang D.F., Myers H.F., Yeung A., Zhang Y., Zhao J., and Yu S. Shenjing shuairuo and the DSM-IV: diagnosis, distress, and disability in a Chinese primary care setting. Transcult Psychiatry 42 (2005) 204-218
9. d'Amato C.C., Pizza V., Marmolo T., Giordano E., Alfano V., and Nasta A. Fluoxetine for migraine prophylaxis: a double-blind trial. Headache 39 (1999) 716-719
10. Dahl A.A., Ravindran A., Allgulander C., Kutcher S.P., Austin C., and Burt T. Sertraline in generalized anxiety disorder: efficacy in treating the psychic and somatic anxiety factors. Acta Psychiatr Scand 111 (2005) 429-435
11. de Waal M.W., Arnold I.A., Eekhof J.A., and van Hemert A.M. Somatoform disorders in general practice: prevalence, functional impairment and comorbidity with anxiety and depressive disorders. Br J Psychiatry 184 (2004) 470-476
12. El-Rufaie O.E., Al-Sabosy M.A., Bener A., and Abuzeid M.S. Somatized mental disorder among primary care Arab patients: I. Prevalence and clinical and sociodemographic characteristics. J Psychosom Res 46 (1999) 549-555
13. Farabaugh A., Mischoulon D., Fava M., Wu S.L., Mascarini A., Tossani E., et al. The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients. Int Clin Psychopharmacol 20 (2005) 87-91
14. Faravelli C., Salvatori S., Galassi F., Aiazzi L., Drei C., and Cabras P. Epidemiology of somatoform disorders: a community survey in Florence. Soc Psychiatry Psychiatr Epidemiol 32 (1997) 24-29
15. Fava M., Rosenbaum J.F., Hoog S.L., Tepner R.G., Kopp J.B., and Nilsson M.E. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord 59 (2000) 119-126
16. Fink P., Sorensen L., Engberg M., Holm M., and Munk-Jorgensen P. Somatization in primary care. Prevalence, health care utilization, and general practitioner recognition. Psychosomatics 40 (1999) 330-338
17. Goldberg D.P., and Blackwell B. Psychiatric illness in general practice. A detailed study using a new method of case identification. Br Med J 1 (1970) 439-443
18. Goodnick P.J., and Goldstein B.J. Selective serotonin reuptake inhibitors in affective disorders-I. Basic pharmacology. 4 12 (1998) S5-S20
19. Goodnick P.J., and Goldstein B.J. Selective serotonin reuptake inhibitors in affective disorders-II. Efficacy and quality of life. J Psychopharmacol 12 (1998) S21-S54
20. Grabe H.J., Meyer C., Hapke U., Rumpf H.J., Freyberger H.J., Dilling H., et al. Specific somatoform disorder in the general population. Psychosomatics 44 (2003) 304-311
21. Greco T., Eckert G., and Kroenke K. The outcome of physical symptoms with treatment of depression. J Gen Intern Med 19 (2004) 813-818
22. Hains B.C., Willis W.D., and Hulsebosch C.E. Serotonin receptors 5-HT1A and 5-HT3 reduce hyperexcitability of dorsal horn neurons after chronic spinal cord hemisection injury in rat. Exp Brain Res 149 (2003) 174-186
23. Katon W., Lin E., Von Korff M., Russo J., Lipscomb P., and Bush T. Somatization: a spectrum of severity. Am J Psychiatry 148 (1991) 34-40
24. Khan A.A., Khan A., Harezlak J., Tu W., and Kroenke K. Somatic symptoms in primary care: etiology and outcome. Psychosomatics 44 (2003) 471-478
25. Kroenke K. Patients presenting with somatic complaints: epidemiology, psychiatric comorbidity and management. Int J Methods Psychiatr Res 12 (2003) 34-43
26. Kroenke K., Spitzer R.L., deGruy III F.V., Hahn S.R., Linzer M., Williams J.B., et al. Multisomatoform disorder. An alternative to undifferentiated somatoform disorder for the somatizing patient in primary care. Arch Gen Psychiatry 54 (1997) 352-358
27. Kroenke K., Spitzer R.L., and Williams J.B. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med 64 (2002) 258-266
28. Kroenke K., Messina III N., Benattia I., Graepel J., and Musgnung J. Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder. J Clin Psychiatry 67 (2006) 72-80
29. Lee R.A., West R.M., and Wilson J.D. The response to sertraline in men with chronic pelvic pain syndrome. Sex Transm Infect 81 (2005) 147-149
30. Leiknes K.A., Finset A., Moum T., and Sandanger I. Current somatoform disorders in Norway: prevalence, risk factors and comorbidity with anxiety, depression and musculoskeletal disorders. Soc Psychiatry Psychiatr Epidemiol 42 9 (2007) 698-710
31. Maier W., and Falkai P. The epidemiology of comorbidity between depression, anxiety disorders and somatic diseases. Int Clin Psychopharmacol 14 Suppl 2 (1999) S1-S6
32. Maurer I., Volz H.P., and Sauer H. Gabapentin leads to remission of somatoform pain disorder with major depression. Pharmacopsychiatry 32 (1999) 255-257
33. Muller T., Mannel M., Murck H., and Rahlfs V.W. Treatment of somatoform disorders with St John's wort: a randomized, double-blind and placebo-controlled trial. Psychosom Med 66 (2004) 538-547
34. O'Malley P.G., Jackson J.L., Santoro J., Tomkins G., Balden E., and Kroenke K. Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract 48 (1999) 980-990
35. O'Malley P.G., Balden E., Tomkins G., Santoro J., Kroenke K., and Jackson J.L. Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Intern Med 15 (2000) 659-666
36. Onghena P., and Van Houdenhove B. Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies. Pain 49 (1992) 205-219
37. Panerai A.E., Monza G., Movilia P., Bianchi M., Francucci B.M., and Tiengo M. A randomized, within-patient, cross-over, placebo-controlled trial on the efficacy and tolerability of the tricyclic antidepressants chlorimipramine and nortriptyline in central pain. Acta Neurol Scand 82 (1990) 34-38
38. Patkar A.A., Masand P.S., Krulewicz S., Mannelli P., Peindl K., Beebe K.L., et al. A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. Am J Med 120 (2007) 448-454
39. Rani P.U., Naidu M.U., Prasad V.B., Rao T.R., and Shobha J.C. An evaluation of antidepressants in rheumatic pain conditions. Anesth Analg 83 (1996) 371-375
40. Russell J.M., Koran L.M., Rush J., Hirschfeld R.M., Harrison W., Friedman E.S., et al. Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression. Depress Anxiety 13 (2001) 18-27
41. Saarto T., and Wiffen P.J. Antidepressants for neuropathic pain. Cochrane Database Syst Rev (2005) CD005454
42. Sanchez C., and Hyttel J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 19 (1999) 467-489
43. Saper J.R., Silberstein S.D., Lake III A.E., and Winters M.E. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache 34 (1994) 497-502
44. Schwarz M.J., Spath M., Muller-Bardorff H., Pongratz D.E., Bondy B., and Ackenheil M. Relationship of substance P, 5-hydroxyindole acetic acid and tryptophan in serum of fibromyalgia patients. Neurosci Lett 259 (1999) 196-198
45. Svensson C.I., Tran T.K., Fitzsimmons B., Yaksh T.L., and Hua X.Y. Descending serotonergic facilitation of spinal ERK activation and pain behavior. FEBS Lett 580 (2006) 6629-6634
46. Tomkins G.E., Jackson J.L., O'Malley P.G., Balden E., and Santoro J.E. Treatment of chronic headache with antidepressants: a meta-analysis. Am J Med 111 (2001) 54-63
47. Turkington D., Grant J.B., Ferrier I.N., Rao N.S., Linsley K.R., and Young A.H. A randomized controlled trial of fluvoxamine in prostatodynia, a male somatoform pain disorder. J Clin Psychiatry 63 (2002) 778-781
48. Vahedi H., Merat S., Rashidioon A., Ghoddoosi A., and Malekzadeh R. The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Aliment Pharmacol Ther 22 (2005) 381-385
49. Van Kempen G.M., Zitman F.G., Linssen A.C., and Edelbroek P.M. Biochemical measures in patients with a somatoform pain disorder, before, during, and after treatment with amitriptyline with or without flupentixol. Biol Psychiatry 31 (1992) 670-680
50. Varia I., Logue E., O'Connor C., Newby K., Wagner H.R., Davenport C., et al. Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin. Am Heart J 140 (2000) 367-372
51. Volz H.P., Moller H.J., Reimann I., and Stoll K.D. Opipramol for the treatment of somatoform disorders results from a placebo-controlled trial. Eur Neuropsychopharmacol 10 (2000) 211-217
52. Volz H.P., Murck H., Kasper S., and Moller H.J. St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. Psychopharmacology (Berl) 164 (2002) 294-300
53. Zhao Z.Q., Chiechio S., Sun Y.G., Zhang K.H., Zhao C.S., Scott M., et al. Mice lacking central serotonergic neurons show enhanced inflammatory pain and an impaired analgesic response to antidepressant drugs. J Neurosci 27 (2007) 6045-6053